Plant-derived polyphenols such as curcumin hold promise as a therapeutic agent in the treatment of chronic liver diseases. However, its development is plagued by poor aqueous solubility resulting in poor bioavailability. To circumvent the suboptimal bioavailability of free curcumin, we have developed a polymeric nanoparticle formulation of curcumin (NanoCurct) that overcomes this major pitfall of the free compound. In this study, we show that NanoCurct results in sustained intrahepatic curcumin levels that can be found in both hepatocytes and non-parenchymal cells. NanoCurct markedly inhibits carbon tetrachloride-induced liver injury, production of pro-inflammatory cytokines and fibrosis. It also enhances antioxidant levels in the liver and inhibits pro-fibrogenic transcripts associated with activated myofibroblasts. Finally, we show that NanoCurct directly induces stellate cell apoptosis in vitro. Our results suggest that NanoCurct might be an effective therapy for patients with chronic liver disease.
Cirrhosis is a wound-healing response to liver injury from a variety of viral, toxin or metabolic insults. Cirrhosis is responsible for as many as 35 000 annual deaths in the United States, unless the progressive degeneration in liver function can be rescued with orthotopic liver transplantation. Histologically, cirrhosis is characterized by excessive extracellular matrix deposition (ie, fibrosis), which surrounds regenerative hepatocellular nodules. In addition to deterioration in liver function, these nodules are also a seedbed for the formation of hepatocellular carcinoma. Hepatocyte injury and chronic inflammation appear to be essential in initiating events for liver fibrosis, leading to activated myofibroblasts. Myofibroblasts can be derived from hepatic stellate or immune cells, or the epithelial-to-mesenchymal transition of hepatocytes or cholangiocytes. 1 In response to the transforming growth factor-b (TGF-b) ligand, the myofibroblasts produce collagen matrix proteins, eventually culminating in fibrosis. 1, 2 Agents that ameliorate hepatic injury or inflammation can serve as a potential antifibrotic therapeutic.
Curcumin or diferuloylmethane is a yellow polyphenol extracted from the rhizome of turmeric (Curcuma longa), a plant grown in tropical Southeast Asia. For centuries, turmeric has been used as a spice and coloring agent in Indian food, as well as a therapeutic agent in traditional Indian medicine. 3 Curcumin has been explored as a promising antineoplastic, 4 antioxidant, 5 anti-inflammatory 6, 7 and antidepressant 8, 9 in animal models. In the liver, Chen and others have shown that oral administration of free curcumin (FC) inhibits liver fibrosis in vivo. 10, 11 Although curcumin has a direct effect on preventing stellate cell activation in vitro, [12] [13] [14] [15] it is not clear if curcumin's antifibrotic activity in vivo is a direct effect in the liver or an indirect systemic effect through the tubular gastrointestinal system.
The potential for using curcumin as a systemic therapeutic has been plagued by poor bioavailability. 16 In rodents, oral gavage with as much as 340 mg/kg of FC results in no detectable curcumin in the liver, although it is present in the gastrointestinal mucosa. 17 Further, oral doses reaching 1000 mg/kg in rodents result in only submicromolar serum concentrations, and even at these levels, there is still no detectable curcumin in the liver. 18 Comparable data exist in limited clinical trials performed in human beings, where 'mega' doses of daily oral FC (up to 8 g per day) mostly results in uptake that is limited to the colonic mucosa, and little, if any, of the active compound reaches the bloodstream or visceral sites. [19] [20] [21] To circumvent the suboptimal systemic bioavailability of FC, we have developed a polymeric nanoparticle formulation of curcumin (NanoCurct) that overcomes this major pitfall of the free compound. 22 In contrast to curcumin, NanoCurct is fully soluble in aqueous media, and shows essentially no toxicity upon daily systemic administration through the intraperitoneal route in mice. Further, at comparable dosages, parenteral NanoCurct shows significant intrahepatic bioavailability, which can be found in both hepatocytes and non-hepatocytes, also referred to as nonparenchymal cells (NPCs). Finally, in this study, we confirm that parenteral NanoCurct can successfully ameliorate the effects of carbon tetrachloride (CCl 4 )-induced liver injury and subsequent fibrosis in rodents. These effects are associated with inhibition of pro-inflammatory cytokines production, enhancing intrahepatic antioxidant levels and reducing pro-fibrogenic transcripts. Finally, we show that the nanoparticle formulation retains the potency of the free compound in inducing apoptosis of pro-fibrotic stellate cells.
MATERIALS AND METHODS Materials
Ultra-pure curcumin (499% diferuloylmethane) was purchased from Sabinsa Corporation (Piscataway, NJ, USA); this source of curcumin has been used for both preclinical and clinical studies in the past. 23, 24 Monomers for polymer nanoparticle synthesis-specifically N-isopropylacrylamide (NIPAAM), vinylpyrrolidone (VP) and acrylic acid (AA)-were obtained from Sigma Aldrich (St Louis, MO, USA). Reagents for the polymerization step, including NN 0 methylene-bis-acrylamide, ammonium persulfate (APS) and ferrous sulfate (FeSO 4 ), were also procured from Sigma.
Synthesis of NanoCurct
Polymer nanoparticles comprising of NIPAAM, VP and AA were synthesized via free radical mechanism, according to the detailed synthesis method we have described previously. 25, 26 The pre-distilled monomers of NIPAAM, VP and AA are mixed together in a molar ratio of 60:20:20, respectively; hence, the acronym 'NVA622' for the resulting polymer. Polymerization was performed for 24 h at 301C under an inert (nitrogen) atmosphere, using APS and FeSO 4 as initiator and activator, respectively. After complete polymerization, the total aqueous solution of polymer was purified using dialysis, and then lyophilized for post-loading of curcumin, as described. 26 Typically, a 10 ml stock solution of polymeric nanoparticles (100 mg) was slowly mixed with 150 ml of curcumin solution in chloroform (10 mg/ml), and gently stirred for 15-20 min on low heating, to load curcumin and evaporate chloroform simultaneously. The resulting solution, corresponding to 1.5% (w/w) loading of curcumin in nanoparticles, was then snap frozen on a dry ice/acetone bath, and lyophilized. The lyophilized NanoCurct powder is stored at 41C until further use, whereupon simple reconstitution in an aqueous phase is required before parenteral administration.
Nanocurc
TM Bioavailability Protocol Male C57BL/6 mice 6-10 weeks of age weighing approximately 25 g were purchased from Charles River (Wilmington, MA, USA). All animals were housed at The Johns Hopkins University animal facility, and handled according to NIH guidelines and protocols approved by the Institutional Animal Care and Use Committee. Mice had free access to food and water in 50-60% relative humidity and 12 h light cycle. Mice received one or three doses of either 1667 mg/kg body weight dose of void nanoparticles and NanoCurct (equivalent to 25 mg/kg body weight of FC) or control phosphate-buffered saline (PBS) via intraperitoneal injection over a 24 h period. Curcumin bioavailability was determined by high-performance liquid chromatography in liver tissue obtained 6 or 24 h after treatment as detailed in Results and Figure 1 legend. Oral gavage was performed by dissolving 25 mg of curcumin in 200 ml of PBS and instilling the resulting fluid into the stomach using a curved gavage needle and syringe. Parenchymal (hepatocytes) and NPCs were isolated by clearing the liver of blood with 50 ml PBS with Ca 2 þ through a portal vein rinse and digesting the liver with 50 ml of collagenase (1.6 mg/ml) in situ. The digested liver was removed, weighed and pressed through a wire mesh into 40 ml of PBS. The resultant homogenate was centrifuged at 50 g for 5 min at 41C The top half of the supernate containing NPC was collected in 50 ml tube and kept on ice for subsequent processing of NPC. The hepatocyte pellet was resuspended in cold PBS and re-pelleted and washed three times with 50 g centrifugations for 5 min at 41C. The supernate NPC fraction was centrifuged at 800 g for 5 min. The resultant pellet was incubated with 5 ml ACK lysis buffer at room temperature to remove the RBCs. It was washed with cold PBS three times. The isolated NPC and parenchymal fractions were counted using a hemocytometer and smeared onto slides, formalin-fixed and stained with hematoxylin-eosin (H&E) histochemical stain for counting to estimate cell purity.
Estimation of Liver Curcumin Levels
Liver and intracellular curcumin levels were measured at the Johns Hopkins Pharmacology Analytical core facility in tissue lysates, using a recently described liquid chromatography/tandem mass spectrometric (LC/MS/MS) approach. 22 CCl 4 Treatment Protocols CCl 4 was administered dissolved in olive oil at a 1:9 ratio through intraperitoneal injection at a dose of 1 mg/g of body weight on days 5, 7, 10 and 12. NanoCurct dissolved in pyrogen free sterile water (Life Technologies, Carlsbad, CA, USA) was given once a day equivalent to 25 mg/kg body weight of FC via intraperitoneal injection on days 1-4, 6, 8, 9, 11 and 13. Mice were harvested on day 14, 24 h after the last NanoCurct injection.
Serum Alanine Aminotransferase
Serum alanine aminotransaminase were determined with a colorimetric kit (Biotron Diagnostics, Hemet, CA, USA), according to the manufacturer's protocol. Briefly, 100 ml of pre-warmed ALT reagent substrate and 20 ml of diluted serum samples were incubated for 30 min at 371C in a water bath. Sodium pyruvate (1.5 mM) was used in graduated concentrations for generating a standard curve. Then, 100 ml of colorimetric reagent (dinitrophenyl hydrazine) was added to all samples and standards and incubated at room temperature. A measure of 1 ml sodium hydroxide was added to each tube, and the absorbance measured at 520 nm.
Enzyme-Linked Immunosorbent Assays
At the time of harvest, liver tissue was weighed and homogenized with 500 ml of RIPA buffer containing complete mini protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA). The lysate was centrifuged at 21 000 g at 41C for 10 min and the clarified supernate was collected and subjected to total protein BCA assay (Pierce, Rockford, IL, USA). Equal total protein was used in an enzyme-linked immunosorbent assay according to the manufacturer's instructions(R & D Systems Minneapolis, MN, USA).
Liver mRNA Isolation and Real-Time RT-PCR Liver tissue was harvested and collected in RNAlater (Sigma Life Science, St Louis, MO, USA). Total RNA was extracted by using RNeasy Min Kit according to the manufacturer's protocol (Qiagen, Valencia, CA, USA). DNase I column digestion was carried out to eliminate the contamination of genomic DNA. cDNA synthesis was carried out using AffinityScript Multi-Temperature cDNA Synthesis Kit (Stratagene, Santa Clara, CA, USA) using random primers and following the manufacturer's protocol.
Quantitative real-time RT-PCR amplification was performed with TaqMan Fast Universal PCR Master Mix with (Applied Biosystem, Carlsbad, CA, USA) without AmpErase UNG using 250 ng of total RNA in a 96-well plate. The real-time RT-PCR was performed with an Applied Biosystem Step One Plus system. The assay ID, the reference sequence, and the exon boundaries used to design the probes and primers are shown in Table 1 . Genes hprt and H2AX were used as references for TNF-a and IL-6, whereas gene hprt was used as reference for COL A, FN-1, TGF-b and PPARG. . Curcumin bioavailability in whole liver tissue was determined by HPLC 6 h after the last dose. (c) Mice (n ¼ 3 in each group) were treated with three i.p. 25 mg/kg doses equally spaced over 24 h of NC, poly and PBS. Hepatocytes (HEPs) and non-parenchymal cells (NPCs) were isolated from the liver. Curcumin bioavailability in HEPs and NPCs was determined by HPLC 6 h after the last dose. Data were expressed as mean ± s.e.m.,*Po0.01, **Po0.001, t-test, from two experiments.
yy indicates below limit of detection.
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Liver Leukocyte Isolation and Flow Cytometry NanoCurct dissolved in pyrogen free sterile water was given once a day equivalent to 25 mg/kg body weight of FC via intraperitoneal injection on days 1, 4 and 6, whereas CCl 4 (1 mg/g of body weight) was administered on days 5 and 7.
Mice were harvested on day 8, 24 h after the last CCl 4 injection. Liver leukocytes were isolated as described previously. 27 Livers were weighed before lymphocyte isolation and total number of isolated leukocytes was determined with a hemocytometer. Equal number of lymphocytes were stained with anti-CD3, Gr1.1 and NK1.1 (BD Bioscience) and subjected to flow cytometry (FACSCaliburt, BD Bioscience). Analysis was performed with the FlowJot software (Tree Star, Ashland, OR, USA).
Histology and Sirius Red Stain for Fibrosis
The medial liver lobe was collected, fixed in methacarn (60% methanol, 30% chloroform, 10% glacial acetic acid), embedded in paraffin and 5-mm sections stained for H&E. For Sirius Red staining (Sigma Aldrich), unstained sections were de-paraffinized in warm xylene and hydrated in graded alcohol and water. Thereafter, nuclei were counterstained with Weigert's hematoxylin for 30 min, and then the slides were rinsed in tap water for 3 min, followed by Sirius Red staining for an hour. This was followed by washing in two changes of acetic acid water, dehydrated in three changes of 100% ethanol, cleared in xylene and mounted in a resinous medium.
Fibrosis Quantification
Ten fields containing no significant staining artifacts (folds or scratches) were randomly selected from each slide. Each field was digitally acquired with 10 Â objective as a 1280 pixel Â 960 pixel JPEG image using a Nikon Eclipse 50i microscope equipped with a Nikon Digital Sight DS-5M camera. To correct for uneven illumination (vignetting), five additional fields were acquired in empty areas of the slide and averaged to produce a single background illumination image. A median filter (radius ¼ 8) was applied to the background illumination image to further reduce potential noise. Custom macros in ImageJ 1.42q (http://www.rsbweb.nih.gov/ij/) were used to measure percent fibrosis. Each image was first converted to 8-bit gray-scale and then corrected for uneven illumination ('shading correction'). Shading correction consisted of dividing an image by its associated background illumination image and then multiplying the result by the median gray value of the background illumination image. After shading correction, an observer manually selected a gray-scale threshold value that best segments the fibrotic areas from the background image. Percent fibrosis was calculated as the area of fibrosis divided by the total image area multiplied by 100.
Estimation of Free and Total Glutathione Levels in Liver Tissue Lysates
Corresponding void polymeric nanoparticles and NanoCurct-treated liver tissue slices were homogenized, extracts were prepared and equal volumes of the extract were subjected to estimation of free and total glutathione (GSH) levels. The results were normalized with protein and amounts of free GSH were measured using the fluorescent-based NADPH substrate and other appropriate reagents (Arbor assay, MI, USA). For estimation of total GSH levels (free plus oxidized), NADPH, GSH reductase and ThioStar reagent were added to the extract and fluorescent signal was read after 15 min, and the activity was calculated. The level of oxidized form of GSH disulfide (GSSG) was estimated from the difference between total vs free GSH. In all instances, a standard curve was prepared before assay performance. All assays were performed in triplicate, and mean and standard deviations were determined.
Hepatic Stellate Cell Line
The immortalized rat liver hepatic stellate cell line, HSC-T6, was a kind gift from Scott L Friedman (Mount Sinai School of Medicine, New York, NY, USA). 28 This line is maintained in DMEM (Life Technologies) supplemented with 5% FBS and the antibiotics penicillin-streptomycin (Life Technologies). Incubation is carried out at 371C in a humidified incubator with 5% CO 2 . Live cells (exclude dye) and dead cells were counted using a hemocytometer. For caspase-3 detection: cells were seeded in a 24-well plate in complete medium overnight and treated for 20 h with varying concentrations (5, 10, 15 and 20 mM) of FC dissolved in 0.1% DMSO or the equivalent amount of NanoCurct dissolved in sterile pyrogen free water. Cells were washed with PBS twice and fixed with 3.7% paraformaldehyde at room temperature for 10 min, washed twice with PBS and denatured in 0.1% Triton X-100 in PBS at room temperature for 10 min. After a two PBS washes, the cells were blocked with 5% fetal bovine albumin at room temperature for 30 min, and then incubated with 1:100 anticleaved caspase-3 (Cell Signaling Technology) solution at room temperature for 1 h. Cells were washed twice with PBS and incubated with 1:300 secondary antibody, Alexa Fluor 568 goat anti-rabbit IgG labeled with bright, orange-redfluorescent Alexa Fluor 568 dye (Invitrogen Corporation) at room temperature for 30 min. Cells were then washed twice with PBS, counterstained with DAPI and observed under a fluorescent microscope.
Apoptosis and Cell Survival Studies

RESULTS
Enhanced Bioavailability of Systemic NanoCurct in Liver Tissue
It has been previously shown that oral intake of up to 400 mg/kg of curcumin may be required for amelioration of liver injury in CCl 4 -treated rodents. 10, 11 In terms of human consumption, these translate into 'mega' doses of several grams (between 8 and 12 g) of curcumin, which becomes untenable in a clinical setting. 29, 30 Furthermore, even intraperitoneal doses of FC result in only ephemeral (min) intrahepatic curcumin delivery. [16] [17] [18] A recently published study using NanoCurct in cancer models shows that a single intraperitoneal dose of this formulation (containing 25 mg/kg of curcumin equivalent) results in peak curcumin plasma levels 4 h after treatment; 22 however, the tissue biodistribution, especially in the liver, was not studied. Using LC-MS/MS, we found significantly greater intrahepatic curcumin concentrations (160 ± 9 ng/g of liver tissue, Po0.001) 12 h after a single 25 mg/kg intraperitoneal injection of NanoCurct compared with control void nanoparticles ( Figure 1a) . As expected, an equivalent dose of FC delivered via oral gavage did not result in any detectable intrahepatic curcumin. As we planned to use multiple doses, we wanted to see if multi-dosing resulted in higher intrahepatic curcumin concentration than a single dose of NanoCurct. Compared with control injection and void nanoparticles, we found significantly higher curcumin concentration (1600±44 ng/g of liver tissue, Po0.001) in the liver 6 h after three equally spaced 25 mg/kg intraperitoneal doses (Figure 1b) . As the liver is a complex tissue made of many cell types, we next wanted to determine if NanoCurct delivered curcumin to parenchymal (hepatocytes) and/or non-parenchymal (all other liver cell types) cells. Mice received three 25 mg/kg NanoCurct doses 8 h apart and were harvested 6 h after the last dose of NanoCurct. The liver was fractionated into parenchymal cells and NPCs. The purity of the NPC fraction (92%) and hepatocyte fraction (96%) was determined by examination of H&E-stained smear preparation of each fraction (Supplementary Figure 1) . We detected significantly more curcumin in hepatocytes (5600 ± 1000 ng/g of hepatocytes, Po0.01) and NPCs (6700 ± 440 ng/g NPCs, Po0.001) compared with void polymer-and vehicle-treated controls (Figure 1c) . We attributed the increase in concentration of curcumin in the hepatocytes and NPC-purified fractions compared with the intact liver (Figure 1c vs b) to regions, perhaps structural, non-cellular components, that contribute to liver weight, but do not absorb curcumin.
NanoCurct Attenuates Hepatocellular Injury and Levels of Pro-Inflammatory Cytokines
First, we wanted to determine if accumulation of intrahepatic curcumin administered as a nanoformulation was capable of suppressing CCl 4 -induced liver injury. Mice received 25 mg/kg intraperitoneal NanoCurct or control injection according to the treatment protocol detailed in Materials and Methods. To provide biochemical evidence of NanoCurct hepatoprotective effects, we collected serum 48 h after the last CCl 4 treatment. Compared with control mice, those that received intraperitoneal NanoCurct showed biochemical evidence of reduced liver injury. Control-treated (310±76 U/ml) mice serum ALT activity was significantly higher compared with NanoCurct-treated mice (55±19 U/ml, Po0.05) (Figure 2a) . Next, we wanted to see if NanoCurct could suppress TNF-a, a pro-inflammatory cytokine associated with CCl 4 -induced liver injury. 31 CCl 4 -induced TNF-a production is a powerful initiator of hepatocyte apoptosis and thought to be one of the important propagators of liver injury. Liver tissues collected 48 h after CCl 4 treatment showed 1.6-fold significantly reduced TNF-a protein concentration in mice treated with NanoCurct compared with controls (Po0.05) (Figure 2b) . We also investigated IL-6, another inflammatory cytokine associated with hepatocellular injury, and TNF-a mRNA induction, and found a significant 2.4-and 1.5-fold reduction in IL-6 and TNF-a, respectively, in NanoCurct-treated mice compared with controls (Po0.001) (Figure 2c and d) . The inflammatory cell milieu after liver injury is complex. 32 The innate immune system is rapidly activated following injury and has been implicated as an important regulator of liver injury and fibrosis. [33] [34] [35] We examined how NanoCurct treatment might alter the innate inflammatory response to CCl 4 . Livers leukocytes were isolated 24 h after the last NanoCurct treatment. There was a slight increase in the total number of inflammatory cells in void nanoparticle (1.9 ± 0.3 lymphocytes per g liver tissue) and NanoCurct (2.2 Â 10 6 ±0.4 lymphocytes per g liver tissue) compared with untreated control mice (1.0 Â 10 6 ±0.5 lymphocytes per g liver tissue); however, this was not statistically significant. Next, we examined CD3 þ NK1.1 þ natural killer T (NKT) cells whose absence makes mice resistant to liver fibrosis, whereas an excess accelerates fibrosis. [36] [37] [38] [39] Consistent to what others have reported, we found NKT cells decreased following CCl 4 treatment. We found 24±1% NKT cells in the liver of untreated wild-type mice, which fell to 12±5% in void nanoparticle and 9±1% in NanoCurct-treated mice that also received CCl 4 38 (Supplementary Figure 2) . There was no significant change in the percentage of NK cells (Supplementary Figure 2) , another innate immune cell implicated in antifibrosis. [39] [40] [41] Lastly, we looked at neutrophil inflammation using Gr-1 high staining. 42 Consistent with what others have reported, 38, 43 CCl 4 enhanced influx of Gr-1 high cells into the liver. Untreated mice had 5%±3 Gr-1 high neutrophils in the liver compared with 13±1% in void nanoparticle-treated mice that also received CCl 4 (Supplementary Figure 2) . Interestingly, mice treated with CCl 4 and NanoCurct also had a significant increase in Gr-1 high cells compared with untreated mice (15 ± 8 vs 5 ± 3%) and was not different compared with mice treated with CCl 4 and void nanoparticles (15 ± 8 vs 13 ± 2%). Taken together, these results support the notion that NanoCurct potently suppresses both hepatocellular injury and pro-inflammatory markers with relatively little effect on innate inflammatory cell infiltrate after CCl 4 challenge.
Systemic NanoCurct Prevents Hepatic Fibrosis in the CCl 4 Model of Liver Injury
If NanoCurct protected against liver injury, it should also prevent the subsequent development of fibrosis that develops following low-dose, repeated CCl 4 administration. 44 Previous studies have established the inhibitory effects of FC on pro-fibrotic hepatic stellate cells in vitro. [12] [13] [14] [15] Nonetheless, given the minimal bioavailability of curcumin in the liver, the relevance of these studies to in vivo observations is not clear. 18 NanoCurct treatment significantly suppressed liver fibrosis three-fold as determined by quantitative image analysis of Sirius Red tissue staining (Figure 3a-d) . NanoCurct administered mice showed only 1.0±0.1% quantifiable fibrosis, whereas control treatment showed 3.0±0.3% (Po0.001) 
NanoCurct Enhances Levels of GSH in the Liver
CCl 4 is activated by centrilobular cytochrome P450 in the liver to form a trichloromethyl radical (CCl 3 K ), which in the absence of oxygen exclusively causes hepatocyte injury through lipid peroxidation. If oxygen is present, the CCl 3 K can rapidly change to a highly reactive peroxytrichloromethyl radical (CCl 3 OO K ). This CCl 3 OO K can also cause hepatocyte injury through lipid peroxidation. 45 Although the CCl 3 K radical's action can predominate in the liver's oxygen poor centrilobular zone, GSH can significantly protect against CCl 3 OO K injury even in extremely low (1%) oxygen tensions. 45 GSH is a major free radical scavenging species in hepatocytes that can protect hepatocytes from oxidative stress 46 and is essential in causing stellate cell apoptosis. 47 For these reasons, we sought to quantify the GSH levels in NanoCurct-treated livers. We quantitatively assessed for levels of free and oxidized GSH in hepatic lysates post-CCl 4 exposure in vehicle-and NanoCurct-treated cohorts. NanoCurct treatment significantly increased levels of free GSH 1.75-fold vs control livers (Po0.01) (Figure 4a) . Interestingly, unlike free GSH, NanoCurct did not significantly alter levels of total GSH (Figure 4b ). NanoCurct treatment did lower oxidized GSSG compared with void nanoparticle treatment, but this was not statistically significant (Figure 4c) , suggesting that the CCl 3 K is a major contributor to lipid peroxidation in our system. Notably, the ratio of free GSH to oxidized GSSG was significantly increased in the NanoCurct-treated cohort vs the vehicle cohort (Po0.04) (Figure 4d ). Although the exact mechanism for the significantly increased free GSH levels in the liver of NanoCurct-treated mice is unclear, the composite results indicate that NanoCurct favorably increases redox capacity of the cells, and thereby can protect liver cells from free radical insults.
NanoCurct Attenuates Transcripts of Pro-Fibrogenic Cytokines Associated with Stellate Cell Activation
In addition to hepatocellular injury and inflammation, a critical initiating component of the fibrogenic responses in the liver is activation of collagen-producing myofibroblasts. 1, 48 To further understand the mechanisms by which NanoCurct might alter myofibroblast responses in the setting of liver injury, we investigated if NanoCurct disrupted production of pro-fibrotic cytokines transcripts. Type I a collagen 49, 50 and fibronectin 1 51, 52 are pro-fibrotic proteins produced by activated myofibroblasts. We found that NanoCurct treatment significantly suppressed mRNA expression of collagen A and fibronectin 1.8-and 1.6-fold, respectively, compared with control void nanoparticle treatment (Po0.001) ( Figure 5) . Notably, NanoCurct treatment reduced these pro-fibrotic transcripts to nearly the basal levels present in untreated mice ( Figure 5 ). We then examined TGF-b, a molecule that has been strongly implicated in the activation of myofibroblast and stimulates collagen production. 53, 54 As expected, void nanoparticle-treated mice Figure 4 NanoCurct increases redox capacity of the hepatocytes. (a) Free glutathione (GSH), (b) oxidized GSH (c), total GSH and (d) the ratio of free GSH to oxidized glutathione disulfide (GSSG) were determined as described in Materials and Methods in liver lysates harvested 48 h after CCl 4 treatment in void polymer-(Poly) and NanoCurct-(NC) treated mice. Data were expressed as mean ± s.e.m., *P values as indicated, t-test, Poly n ¼ 4, NC n ¼ 5.
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showed a 2.6-fold increase in TGF-b expression while NanoCurct treatment significantly and completely abrogated expression (Po0.001) ( Figure 5 ). In vitro studies have shown the importance of the nuclear transcription factor peroxisome proliferator-activated receptor g (PPAR-g) in controlling myofibroblast activation and its requirement in promoting curcumin-induced apoptosis. 15, [55] [56] [57] There was significant inhibition of PPAR-g expression in void nanoparticle-treated mice, whereas NanoCurct significantly induced a 14 -fold expression of PPAR-g compared with void nanoparticle treatment (Po0.001) ( Figure 5 ). Collectively, these data support NanoCurct ability to inhibit fibrosis through suppression of pro-fibrogenic transcripts and suggest that NanoCurct might induce myofibroblast apoptosis through activation of PPAR-g. NanoCurct Treatment Induces Hepatic Stellate Cell Apoptosis An important, but not the sole source of activated myofibroblasts is hepatic stellate cells. 1 We wanted to determine if NanoCurct was capable of inducing stellate cell apoptosis as has been reported for FC. 15, 58 In vitro hepatic stellate cells were treated with equivalent concentrations of curcumin, NanoCurct or vehicle control for 24 h . We found a significant and dose-dependent decrease in the number of viable stellate cells in curcumin-and NanoCurct-treated cultures compared with controls (Figure 6a-c) . The same trend was found whether we assayed with dye exclusion (Figure 6d ) or the apoptosis marker cleaved caspase-3 (Supplementary Figure 3) . As expected, the nanoencapsulation of curcumin did not alter its biological activity in vitro.
26
DISCUSSION
Hepatic injury and fibrosis develops in response to a wide array of etiologies such as viral infection, toxin exposure, alcohol abuse and metabolic diseases. 59 Persistent injury leads to inflammation, fibrosis and compensatory hepatocyte hyperplasia usually cumulating in cirrhosis. Any treatment that can prevent hepatocellular injury, inflammation or fibrosis is a potential therapeutic for preventing cirrhosis in the setting of chronic liver disease. Chronic liver disease is the third leading cause for hospital visits in the United States, resulting in 5.9 million visits in 2004 and nearly 30 000 annual deaths. 60 Given this considerable disease burden, there is intense interest in developing therapies aimed at chronic liver disease.
Plant-derived polyphenols are increasingly being recognized for their medicinal potential. 16 Curcumin is a yellow polyphenol extracted from the rhizome of turmeric (C. longa), which has been used as a spice, coloring agent and as a therapeutic agent in traditional Indian medicine. 3 Curcumin's promising antineoplastic, 4 antioxidant, 5 antiinflammatory 6, 7 and antidepressant 8, 9 activities have been explored in animals. In vitro and in vivo studies have explored curcumin's antifibrotic potential in the liver. [10] [11] [12] [13] [14] [15] However, its promise is plagued by the lack of bioavailable curcumin in liver even following massive oral doses. 18 Although curcumin formulated with phosphatidylcholine (Meriva s ) enhances oral absorption and results in detectable intrahepatic curcumin, it is only detectable up to 2 h after dosing. 17 The lack of water solubility is the primary problem limiting curcumin's therapeutic development.
To address the lack of solubility, we developed a biocompatible nanomaterial to provide an opportunity for harnessing the full potential of a potent, yet poorly soluble compounds like curcumin. [61] [62] [63] We have developed polymeric nanoparticles comprised of NIPAAM, MMA and AA that are capable of solubilizing a broad range of poorly watersoluble drugs. Curcumin encapsulated in these polymeric nanoparticles, NanoCurct, is fully soluble in aqueous media, and shows essentially no toxicity upon daily systemic administration through the intraperitoneal route in mice.
In this study, we found that NanoCurct delivers a substantial concentration of curcumin to the liver. As early as 6 h after multiple doses and as long as 12 h after a signal dose, a significant amount of curcumin is detected in the liver. The curcumin is detectable in hepatocytes isolated from the liver. This might explain why we see a significant reduction in CCl 4 -induced hepatocellular injury and production of proinflammatory cytokines (Figure 2 ). The exact mechanism by Figure 5 NanoCurct attenuates genes associated with stellate cell activation and fibrosis while stimulating pro-apoptotic gene expression. Liver tissue harvested from untreated mice (PBS), void polymer (Poly) or NanoCurct (NC) injections along with carbon tetrachloride (CCl 4 ) according to the treatment protocol in Materials and Methods. Gene expression levels for transcripts encoding for Collagen A (COL A), fibronectin 1 (FN-1), transforming growth factor-b (TGFB) and peroxisome proliferator-activated receptor gamma (PPARG) were determined after isolation of RNA with real-time reverse transcription-polymerase chain reaction (RT-PCR). Gene expression was normalized with hprt and fold expression was determined using the DDC t method in which untreated liver tissue was set to relative expression level of 1.0. Data were expressed as mean ± s.e.m., **Po0.001, in comparing Ctrl vs NC, t-test; control n ¼ 4, NC n ¼ 5, representative of two experiments.
NanoCurct ameliorates hepatic injury and fibrosis S Bisht et al which curcumin induces a protective hepatocellular environment is not clear. The ability of GSH to prevent CCl 4 liver injury is limited as the low oxygen tensions in the centrilobular zones limit formation of the CCl 3 OO K that GSH could reduce. Another possibility is the inhibition of the CCl 3 free radical formation, which is required for CCl 4 -mediated liver injury. The formation of the free radical requires cytochrome P450, which is a known target of curcumin. [64] [65] [66] Although we see the delivery of curcumin to hepatocytes as overcoming a significant limitation in the therapeutic development of curcumin, the need to deliver curcumin to hepatocytes is not clear. Others studies have shown large daily oral doses of FC can inhibit CCl 4 -induced fibrosis in rats. 11 However, this delivery route results in detectable curcumin in the gastrointestinal tract, but not in the liver. 10 This suggests that curcumin might work through multiple mechanisms.
We also found that NanoCurct treatment results in a significant amount of curcumin in the NPC compartment. Although the cellular make-up of this compartment is complex, it does contain pro-fibrotic stellate cells and myofibroblasts. Lipid-laden cells, likely stellate cells, were evident in the NPC fraction (Supplementary Figure 1, green arrows) . This is important, as there is considerable in vitro evidence that curcumin directly induces stellate cell apoptosis and blocks stellate cell activation. 10, 67 These previous studies bolster our conclusions as we know that the NanoCurct formulation does not alter its biological activity. NanoCurct is equally effective as the unencapsulated form at inducing stellate cell apoptosis ( Figure 6 ). However, this is not entirely surprising as NanoCurct bio-effectiveness is comparable to the free parent compound in a cancer system. 26 We also provide in vivo evidence of NanoCurct effectiveness in preventing stellate cell activation as it induces PPAR-g transcription, an essential mediator of curcumin's effects on eliminating stellate cells. 15 As our data show that NanoCurct protects the liver from injury, it could be argued that NanoCurct is more hepatoprotective than antifibrotic. However, it is likely that NanoCurct is working at multiple steps in the development of fibrosis. First, as already mentioned, NanoCurct prevents hepatocellular injury. However, this is not a complete suppression of injury. There is slight but measurable hepatocellular injury in NanoCurct-treated mice as evidence by the increase in serum ALT and intrahepatic TNF-a compared with untreated mice (Figure 2 ). The same is true for the production of the potent pro-fibrotic cytokine TGF-b ( Figure 5) . We also present evidence of effects of curcumins on pro-fibrotic stellate cells through the induction of PPAR-g ( Figure 5 ). Collectively, our findings suggest that NanoCurct works at multiple steps in the injury and fibrosis pathway. This agent could be particularly useful in preventing the progression of chronic liver disease in patients with active on-going liver injury such as in viral or autoimmune hepatitis as it targets both liver injury and fibrosis mechanisms.
Hepatic inflammation is central to many liver diseases. 32 Interestingly, our data show that NanoCurct has little effect on NKT cells and neutrophils in the liver. There is a comparable decrease in NKT and increase in Gr-1 high cells in void nanoparticle and NanoCurct-treated mice (Supplementary Figure 2) . This is consistent with what has been reported in wild-type CCl 4 -treated mice. 38 This could indicate that a low level of injury is sufficient to affect the immune system or that another important component of the innate immune system, particularly Kupffer cells, 68 might be targeted by NanoCurct. More immediate 24 h studies and analysis of chemokines might be more revealing in dissecting NanoCurct's potential role in altering the livers inflammatory milieu.
The results of this study show NanoCurct feasibility in treating chronic liver diseases. Being fully water soluble, NanoCurct overcomes the most important road block that prevented curcumin's clinical development, further showing that NanoCurct prevents liver injury and fibrosis is a significant developmental step in bringing this natural compound to clinical trials.
